>>> Allergan : Reiterates FY15 EPS +20-25%, Rev up double digits; Reiterates FY1


Reiterates FY15 EPS +20-25%, Rev up double digits; Reiterates FY14 EPS $5.64-5.73 v $5.69e, Rev $6.77-7.0B v $7.0Be - conf slides

Long term guidance CAGR: EPS +20%, Rev up double digits To see additional free cash flow of ~$14B over five years and significant borrowing capacity to drive strategic options and financial flexibility